miR-214 promotes apoptosis and sensitizes breast cancer cells to doxorubicin by targeting the RFWD2-p53 cascade.
作者： Jiaxuan Zhang , Beibei Su , Chen Gong , Qingsongg Xi , Tengfei Chao
DOI: 10.1016/J.BBRC.2016.07.054
关键词:
摘要: miR-214 is involved in numerous physiological and pathological processes including tumorigenesis. However, the function of development treatment breast cancer remains elusive. In this study, we report that strikingly down-regulated cell lines clinical samples, particularly, doxorubicin resistant tumor tissues. Remarkably, restoration expression induces apoptosis sensitizes MCF7 cells sustaining wild-type p53, but not p53 null MDA-MB-157 cells, to doxorubicin. Furthermore, reveal directly down-regulates RFWD2, also known as COP1, an E3 ligase targeting suppressor for proteasomal degradation. addition, RFWD2 protein levels are reversely correlated with Moreover, ectopic markedly abolishes miR-214-triggered cells. conclusion, functions a by regulating RFWD2-p53 cascade, thus delivery analogs could be potential adjunct therapy harboring wild type p53.
sci-hub.se 参考文章(26)
Scott W. Lowe, H.Earl Ruley, Tyler Jacks, David E. Housman, p53-dependent apoptosis modulates the cytotoxicity of anticancer agents Cell. ,vol. 74, pp. 957- 967 ,(1993) , 10.1016/0092-8674(93)90719-7
Fang Wang, Min Liu, Xin Li, Hua Tang, MiR‐214 reduces cell survival and enhances cisplatin‐induced cytotoxicity via down‐regulation of Bcl2l2 in cervical cancer cells FEBS Letters. ,vol. 587, pp. 488- 495 ,(2013) , 10.1016/J.FEBSLET.2013.01.016
Teng-fei Chao, Hui-hua Xiong, Wei Liu, Yang Chen, Jia-xuan Zhang, MiR-21 mediates the radiation resistance of glioblastoma cells by regulating PDCD4 and hMSH2 Journal of Huazhong University of Science and Technology [Medical Sciences]. ,vol. 33, pp. 525- 529 ,(2013) , 10.1007/S11596-013-1153-4
Zhi-wei Yu, Lai-ping Zhong, Tong Ji, Ping Zhang, Wan-tao Chen, Chen-ping Zhang, MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines Oral Oncology. ,vol. 46, pp. 317- 322 ,(2010) , 10.1016/J.ORALONCOLOGY.2010.02.002
George W. Sledge, Donna Neuberg, Patricia Bernardo, James N. Ingle, Silvana Martino, Eric K. Rowinsky, William C. Wood, Phase III Trial of Doxorubicin, Paclitaxel, and the Combination of Doxorubicin and Paclitaxel as Front-Line Chemotherapy for Metastatic Breast Cancer: An Intergroup Trial (E1193) Journal of Clinical Oncology. ,vol. 21, pp. 588- 592 ,(2003) , 10.1200/JCO.2003.08.013
David Dornan, Ingrid Wertz, Harumi Shimizu, David Arnott, Gretchen D. Frantz, Patrick Dowd, Karen O' Rourke, Hartmut Koeppen, Vishva M. Dixit, The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature. ,vol. 429, pp. 86- 92 ,(2004) , 10.1038/NATURE02514
Benjamin P. Lewis, Christopher B. Burge, David P. Bartel, Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets Cell. ,vol. 120, pp. 15- 20 ,(2005) , 10.1016/J.CELL.2004.12.035
Assia Derfoul, Aster H. Juan, Michael J. Difilippantonio, Nallasivam Palanisamy, Thomas Ried, Vittorio Sartorelli, Decreased microRNA-214 levels in breast cancer cells coincides with increased cell proliferation, invasion and accumulation of the Polycomb Ezh2 methyltransferase. Carcinogenesis. ,vol. 32, pp. 1607- 1614 ,(2011) , 10.1093/CARCIN/BGR184
Flora Zagouri, Theodoros N Sergentanis, Alexandra Tsigginou, Constantine Dimitrakakis, George C Zografos, Meletios-Athanassios Dimopoulos, Theodora Psaltopoulou, None, Female breast cancer in Europe: statistics, diagnosis and treatment modalities. Journal of Thoracic Disease. ,vol. 6, pp. 589- 590 ,(2014) , 10.3978/J.ISSN.2072-1439.2014.06.18
Hua Yang, William Kong, Lili He, Jian-Jun Zhao, Joshua D. O'Donnell, Jiawang Wang, Robert M. Wenham, Domenico Coppola, Patricia A. Kruk, Santo V. Nicosia, Jin Q. Cheng, MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Research. ,vol. 68, pp. 425- 433 ,(2008) , 10.1158/0008-5472.CAN-07-2488